<p>根據彭博社報道，摩根大通分析師將 Centessa Pharmaceuticals（納斯達克股票代碼：CNTA）的評級從&#34;持平&#34;調高至&#34;超配&#34;，並在週四向客户和投資者發佈的研究報告中指出，該券商目前將該股票的目標價格定為 26.00 美元，高於之前的 11.00 美元。摩根大通的目標價格表明，該公司的股價有望比前一交易日上漲 64.04%。</p>
<p>其他分析師也發佈了關於該股票的研究報告。Jefferies Financial Group 將 Centessa Pharmaceuticals 的目標股價從 13.00 美元上調至 19.00 美元，並在 9 月 11 日星期三的研究報告中給予該股票&#34;買入&#34;評級。BMO Capital Markets 將 Centessa Pharmaceuticals 的目標股價從 20.00 美元上調至 35.00 美元，並在週一的報告中給予該股票&#34;表現優異&#34;評級。B. Riley 在週四的一份研究報告中開始對 Centessa Pharmaceuticals 進行覆蓋。他們給予該公司&#34;買入&#34;評級，並設定了 33.00 美元的目標股價。Guggenheim 將 Centessa Pharmaceuticals 的目標股價從 20.00 美元上調至 24.00 美元，並在 9 月 11 日星期三的研究報告中給予該股票&#34;買入&#34;評級。最後，Oppenheimer 在 8 月 14 日星期三的一份研究報告中重申了&#34;表現優異&#34;評級，並設定了 14.00 美元的目標股價。根據 MarketBeat.com 的數據，共有六位股票研究分析師對該股票給予了&#34;買入&#34;評級，Centessa Pharmaceuticals 目前的平均評級為&#34;買入&#34;，平均目標股價為 25.17 美元。</p>
<p><strong>查看我們關於 Centessa Pharmaceuticals 的最新報告</strong></p>
<h2>Centessa Pharmaceuticals 股價表現</h2>
<p>週四，納斯達克股票代碼為 CNTA 的股票上漲了 0.14 美元，報價為 15.85 美元。該公司的交易量為 811,734 股，相比平均交易量 388,219 股有所增加。該公司的流動比率為 13.29，速動比率為 13.29，負債權益比為 0.27。該公司的市值為 15.9 億美元，市盈率為-11.16，貝塔係數為 1.44。Centessa Pharmaceuticals 的 52 周最低價為 5.15 美元，52 周最高價為 17.59 美元。該企業的 50 日移動平均價格為 12.15 美元，200 日移動平均價格為 10.60 美元。</p>
<p>Centessa Pharmaceuticals（納斯達克股票代碼：CNTA）於 8 月 13 日星期二發佈了最新的財報。該公司報告稱，該季度每股收益為-0.40 美元，低於分析師預期的-0.38 美元。作為一組，股票分析師預計 Centessa Pharmaceuticals 本財年的每股收益為-1.61 美元。</p>
<h2>Centessa Pharmaceuticals 內部交易</h2>
<p>根據其他 Centessa Pharmaceuticals 的消息，內部人員 Gregory M. Weinhoff 於 8 月 22 日星期四出售了 12,198 股公司股票。這些股票的平均價格為 12.17 美元，總交易額為 148,449.66 美元。交易完成後，該內部人員現在直接持有公司 241,171 股股票，價值 2,935,051.07 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過此鏈接獲得。此外，CEO Saurabh Saha 於 9 月 10 日星期二出售了 175,000 股股票。這些股票的平均價格為 16.52 美元，總價值為 2,891,000.00 美元。交易完成後，首席執行官現在持有公司 776,924 股股票，價值 12,834,784.48 美元。該交易已在美國證券交易委員會的申報文件中披露，可通過此超鏈接訪問。此外，內部人員 Gregory M. Weinhoff 於 8 月 22 日星期四出售了 12,198 股公司股票。這些股票的平均價格為 12.17 美元，總交易額為 148,449.66 美元。交易完成後，該內部人員現在直接持有公司 241,171 股股票，價值 2,935,051.07 美元。有關此交易的披露信息可在此處找到。內部人員在過去三個月內共出售了價值 3,472,000 美元的公司股票，目前公司股份的 11.59% 由內部人員持有。</p>
<h2>機構投資者對 Centessa Pharmaceuticals 的看法</h2>
<p>對沖基金和其他機構投資者最近增加或減少了他們在該公司的持股。Nantahala Capital Management LLC 在第二季度購入了 Centessa Pharmaceuticals 的新頭寸，價值約 4,064,000 美元。Perceptive Advisors LLC 在第二季度將其對 Centessa Pharmaceuticals 的持股增加了 27.6%。Perceptive Advisors LLC 現在擁有公司 3,933,307 股股票，價值 35,518,000 美元，比上一季度增加了 850,000 股。Quarry LP 在第二季度增持了 Centessa Pharmaceuticals 的股份，持股增長了 47.8%。Quarry LP 現在擁有公司 9,608 股股票，價值 87,000 美元，比上一季度增加了 3,108 股。Driehaus Capital Management LLC 在第二季度將其對 Centessa Pharmaceuticals 的持股增加了 89.5%。Driehaus Capital Management LLC 現在擁有公司 2,092,011 股股票，價值 18,891,000 美元，比上一季度增加了 987,997 股。最後，The Manufacturers Life Insurance Company 在第二季度將其對 Centessa Pharmaceuticals 的持股增加了 30.4%。The Manufacturers Life Insurance Company 現在擁有公司 140,894 股股票，價值 1,272,000 美元，比上一季度增加了 32,846 股。對沖基金和其他機構投資者擁有公司 82.01% 的股份。</p>
<h2>關於 Centessa Pharmaceuticals（獲取免費報告）</h2>
<p>Centessa Pharmaceuticals plc 是一家臨牀階段的製藥公司，致力於發現、開發和提供藥物給患者。其產品管線包括 SerpinPC，一種活化蛋白 C 抑制劑，目前正在 IIa 期臨牀開發，用於治療血友病 A 和 B；以及 ORX750，一種口服 OX2R 激動劑，用於治療 NT1，並有潛力擴展至其他睡眠障礙。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們比 Centessa Pharmaceuticals 更喜歡的股票</li>
<li>投資石油股的方法和原因</li>
<li>Edgewise Therapeutics 股價飆升 50%：漲勢背後的關鍵原因</li>
<li>房地產投資信託在您的投資組合中應該佔據什麼位置？</li>
<li>聯邦儲備降息如何加速這 3 只 ETF 的增長</li>
<li>股票平均計算器</li>
<li>微軟股票：它準備在第四季度大幅領先的 3 個原因</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ “我將為您提供所需的知識和信心，在五天或更短的時間內進行您的第一筆期權交易... 保證！”（來自 InvestorPlace）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NjEz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NjEz"/></p>
<h2>現在是否值得投資$1,000 在 Centessa Pharmaceuticals？</h2>
<p>在考慮 Centessa Pharmaceuticals 之前，您需要聽到這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票清單... 而 Centessa Pharmaceuticals 不在其中。</p>
<p>雖然 Centessa Pharmaceuticals 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CNTA

<p>摩根大通（Morgan Stanley）將 Centessa Pharmaceuticals（納斯達克股票代碼：CNTA）的評級從 “持平” 調升至 “增持”，並將目標股價從$X.00 上調至$Y.00，顯示潛在上漲空間為 64.04%。其他分析師，包括 Jefferies 和 BMO Capital Markets，也提高了他們的目標股價和評級。Centessa 的股價為$Z.85，市值為$A.59 十億美元。最近的內部交易包括首席執行官 Saurabh Saha 和 Gregory M. Weinhoff 的大量股票銷售。機構投資者也調整了他們在該公司的持股</p>

<p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) was upgraded by analysts at Morgan Stanley from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a $26.00 price objective on the stock, up from their prior price objective of $11.00. Morgan Stanley's target price points to a potential upside of 64.04% from the company's previous close.</p>
<div class="lb-trans"><p>根據彭博社報道，摩根大通分析師將 Centessa Pharmaceuticals（納斯達克股票代碼：CNTA）的評級從&#34;持平&#34;調高至&#34;超配&#34;，並在週四向客户和投資者發佈的研究報告中指出，該券商目前將該股票的目標價格定為 26.00 美元，高於之前的 11.00 美元。摩根大通的目標價格表明，該公司的股價有望比前一交易日上漲 64.04%。</p>
</div><p>Other analysts have also issued research reports about the stock. Jefferies Financial Group raised their target price on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, September 11th. BMO Capital Markets raised their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday. B. Riley assumed coverage on Centessa Pharmaceuticals in a research note on Thursday. They issued a &#34;buy&#34; rating and a $33.00 target price for the company. Guggenheim raised their price target on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, September 11th. Finally, Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of &#34;Buy&#34; and an average target price of $25.17.</p>
<div class="lb-trans"><p>其他分析師也發佈了關於該股票的研究報告。Jefferies Financial Group 將 Centessa Pharmaceuticals 的目標股價從 13.00 美元上調至 19.00 美元，並在 9 月 11 日星期三的研究報告中給予該股票&#34;買入&#34;評級。BMO Capital Markets 將 Centessa Pharmaceuticals 的目標股價從 20.00 美元上調至 35.00 美元，並在週一的報告中給予該股票&#34;表現優異&#34;評級。B. Riley 在週四的一份研究報告中開始對 Centessa Pharmaceuticals 進行覆蓋。他們給予該公司&#34;買入&#34;評級，並設定了 33.00 美元的目標股價。Guggenheim 將 Centessa Pharmaceuticals 的目標股價從 20.00 美元上調至 24.00 美元，並在 9 月 11 日星期三的研究報告中給予該股票&#34;買入&#34;評級。最後，Oppenheimer 在 8 月 14 日星期三的一份研究報告中重申了&#34;表現優異&#34;評級，並設定了 14.00 美元的目標股價。根據 MarketBeat.com 的數據，共有六位股票研究分析師對該股票給予了&#34;買入&#34;評級，Centessa Pharmaceuticals 目前的平均評級為&#34;買入&#34;，平均目標股價為 25.17 美元。</p>
</div><p><strong>View Our Latest Report on Centessa Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Centessa Pharmaceuticals 的最新報告</strong></p>
</div><h2>Centessa Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 股價表現</h2>
</div><p>Shares of NASDAQ:CNTA traded up $0.14 on Thursday, hitting $15.85. The company had a trading volume of 811,734 shares, compared to its average volume of 388,219. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. The company has a market cap of $1.59 billion, a PE ratio of -11.16 and a beta of 1.44. Centessa Pharmaceuticals has a 52-week low of $5.15 and a 52-week high of $17.59. The business has a 50 day moving average of $12.15 and a 200 day moving average of $10.60.</p>
<div class="lb-trans"><p>週四，納斯達克股票代碼為 CNTA 的股票上漲了 0.14 美元，報價為 15.85 美元。該公司的交易量為 811,734 股，相比平均交易量 388,219 股有所增加。該公司的流動比率為 13.29，速動比率為 13.29，負債權益比為 0.27。該公司的市值為 15.9 億美元，市盈率為-11.16，貝塔係數為 1.44。Centessa Pharmaceuticals 的 52 周最低價為 5.15 美元，52 周最高價為 17.59 美元。該企業的 50 日移動平均價格為 12.15 美元，200 日移動平均價格為 10.60 美元。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). As a group, equities analysts anticipate that Centessa Pharmaceuticals will post -1.61 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（納斯達克股票代碼：CNTA）於 8 月 13 日星期二發佈了最新的財報。該公司報告稱，該季度每股收益為-0.40 美元，低於分析師預期的-0.38 美元。作為一組，股票分析師預計 Centessa Pharmaceuticals 本財年的每股收益為-1.61 美元。</p>
</div><h2>Insider Transactions at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 內部交易</h2>
</div><p>In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 12,198 shares of the business's stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total transaction of $148,449.66. Following the completion of the sale, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 175,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00. Following the completion of the sale, the chief executive officer now owns 776,924 shares of the company's stock, valued at $12,834,784.48. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Gregory M. Weinhoff sold 12,198 shares of the business's stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $12.17, for a total transaction of $148,449.66. Following the transaction, the insider now directly owns 241,171 shares in the company, valued at $2,935,051.07. The disclosure for this sale can be found here. Insiders have sold a total of 216,873 shares of company stock worth $3,472,000 in the last three months. 11.59% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>根據其他 Centessa Pharmaceuticals 的消息，內部人員 Gregory M. Weinhoff 於 8 月 22 日星期四出售了 12,198 股公司股票。這些股票的平均價格為 12.17 美元，總交易額為 148,449.66 美元。交易完成後，該內部人員現在直接持有公司 241,171 股股票，價值 2,935,051.07 美元。該交易已在美國證券交易委員會的法律文件中披露，可通過此鏈接獲得。此外，CEO Saurabh Saha 於 9 月 10 日星期二出售了 175,000 股股票。這些股票的平均價格為 16.52 美元，總價值為 2,891,000.00 美元。交易完成後，首席執行官現在持有公司 776,924 股股票，價值 12,834,784.48 美元。該交易已在美國證券交易委員會的申報文件中披露，可通過此超鏈接訪問。此外，內部人員 Gregory M. Weinhoff 於 8 月 22 日星期四出售了 12,198 股公司股票。這些股票的平均價格為 12.17 美元，總交易額為 148,449.66 美元。交易完成後，該內部人員現在直接持有公司 241,171 股股票，價值 2,935,051.07 美元。有關此交易的披露信息可在此處找到。內部人員在過去三個月內共出售了價值 3,472,000 美元的公司股票，目前公司股份的 11.59% 由內部人員持有。</p>
</div><h2>Institutional Investors Weigh In On Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Centessa Pharmaceuticals 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new position in Centessa Pharmaceuticals in the 2nd quarter valued at about $4,064,000. Perceptive Advisors LLC lifted its stake in shares of Centessa Pharmaceuticals by 27.6% in the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company's stock worth $35,518,000 after acquiring an additional 850,000 shares in the last quarter. Quarry LP boosted its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company's stock valued at $87,000 after purchasing an additional 3,108 shares during the last quarter. Driehaus Capital Management LLC grew its stake in Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock valued at $18,891,000 after purchasing an additional 987,997 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Centessa Pharmaceuticals by 30.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,894 shares of the company's stock worth $1,272,000 after purchasing an additional 32,846 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近增加或減少了他們在該公司的持股。Nantahala Capital Management LLC 在第二季度購入了 Centessa Pharmaceuticals 的新頭寸，價值約 4,064,000 美元。Perceptive Advisors LLC 在第二季度將其對 Centessa Pharmaceuticals 的持股增加了 27.6%。Perceptive Advisors LLC 現在擁有公司 3,933,307 股股票，價值 35,518,000 美元，比上一季度增加了 850,000 股。Quarry LP 在第二季度增持了 Centessa Pharmaceuticals 的股份，持股增長了 47.8%。Quarry LP 現在擁有公司 9,608 股股票，價值 87,000 美元，比上一季度增加了 3,108 股。Driehaus Capital Management LLC 在第二季度將其對 Centessa Pharmaceuticals 的持股增加了 89.5%。Driehaus Capital Management LLC 現在擁有公司 2,092,011 股股票，價值 18,891,000 美元，比上一季度增加了 987,997 股。最後，The Manufacturers Life Insurance Company 在第二季度將其對 Centessa Pharmaceuticals 的持股增加了 30.4%。The Manufacturers Life Insurance Company 現在擁有公司 140,894 股股票，價值 1,272,000 美元，比上一季度增加了 32,846 股。對沖基金和其他機構投資者擁有公司 82.01% 的股份。</p>
</div><h2>About Centessa Pharmaceuticals (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Centessa Pharmaceuticals（獲取免費報告）</h2>
</div><p>Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家臨牀階段的製藥公司，致力於發現、開發和提供藥物給患者。其產品管線包括 SerpinPC，一種活化蛋白 C 抑制劑，目前正在 IIa 期臨牀開發，用於治療血友病 A 和 B；以及 ORX750，一種口服 OX2R 激動劑，用於治療 NT1，並有潛力擴展至其他睡眠障礙。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>How the Fed’s Rate Cut Could Supercharge These 3 ETFs</li>
<li>Stock Average Calculator</li>
<li>Microsoft Stock: 3 Reasons It’s Ready to Crush Q4</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>五隻我們比 Centessa Pharmaceuticals 更喜歡的股票</li>
<li>投資石油股的方法和原因</li>
<li>Edgewise Therapeutics 股價飆升 50%：漲勢背後的關鍵原因</li>
<li>房地產投資信託在您的投資組合中應該佔據什麼位置？</li>
<li>聯邦儲備降息如何加速這 3 只 ETF 的增長</li>
<li>股票平均計算器</li>
<li>微軟股票：它準備在第四季度大幅領先的 3 個原因</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ “I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!” (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ “我將為您提供所需的知識和信心，在五天或更短的時間內進行您的第一筆期權交易... 保證！”（來自 InvestorPlace）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NjEz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9613&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Centessa Pharmaceuticals right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Centessa Pharmaceuticals？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Centessa Pharmaceuticals 之前，您需要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票清單... 而 Centessa Pharmaceuticals 不在其中。</p>
</div><p>While Centessa Pharmaceuticals currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Centessa Pharmaceuticals 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Centessa Pharmaceuticals（納斯達克股票代碼：CNTA）被摩根士丹利上調至 “增持” 評級